Jun 14, 2023 / 05:40PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
Welcome to the conference. My name is Chris Shibutani, I'm a member of the research effort. All the hard work gets done by Stephen Sloan, who's joining me up stage here. Entrada, ticker TRDA, we've known you guys for a couple of years. We're really pleased to have you join us once again, Dipal Doshi, President and CEO; and Natarajan Sethuraman, Chief Scientific Officer. So the business powerhouse through scientific trust.
Entrada, even the name of the company has a meaning in terms of foundationally what you guys do. And we're going to get into the details, and Stephen Sloan will ask all the relevant precise questions that think about the model and your pipeline, et cetera.
Questions and Answers:
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research AnalystIt's almost [majority] say that you're like a drug delivery company. But within that, there is just really a platform and there are strategic decisions that you've made about sort of like
Trustpilot
